Commercial success is limited by not having enough money to throw at trials. If they could have raised $70-$100 mill (no problem for Sarepta), we’d be nearing completion of the original pivotal trial.
IMO has more to do with structure of ANP (and that it doesn’t have new drugs in internal development) than managerial competence, though our history doesn’t help.
- Forums
- ASX - By Stock
- Sarepta FDA Hearing
Commercial success is limited by not having enough money to...
-
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.5¢ |
Change
0.001(1.35%) |
Mkt cap ! $67.61M |
Open | High | Low | Value | Volume |
7.7¢ | 7.8¢ | 7.4¢ | $24.63K | 325.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 142779 | 7.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.5¢ | 8181 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 142779 | 0.073 |
2 | 147362 | 0.072 |
2 | 310000 | 0.071 |
4 | 34299 | 0.070 |
2 | 28980 | 0.069 |
Price($) | Vol. | No. |
---|---|---|
0.075 | 8181 | 1 |
0.078 | 125476 | 3 |
0.079 | 175123 | 2 |
0.080 | 287231 | 3 |
0.081 | 125000 | 2 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |